Basigin deficiency prevents anaplerosis and ameliorates insulin resistance and hepatosteatosis.
Basigin deficiency prevents anaplerosis and ameliorates insulin resistance and hepatosteatosis.
复制标题
Basigin缺乏可防止同体,并改善胰岛素抵抗和肝抑制病。
DOI:
10.1172/jci.insight.142464
复制
发表时间:
2021-10-22
期刊:
影响因子:
8
通讯作者:
Kadomatsu K
中科院分区:
文献类型:
--
作者:
Ryuge A;Kosugi T;Maeda K;Banno R;Gou Y;Zaitsu K;Ito T;Sato Y;Hirayama A;Tsubota S;Honda T;Nakajima K;Ozaki T;Kondoh K;Takahashi K;Kato N;Ishimoto T;Soga T;Nakagawa T;Koike T;Arima H;Yuzawa Y;Minokoshi Y;Maruyama S;Kadomatsu K
Monocarboxylates, such as lactate and pyruvate, are precursors for biosynthetic pathways, including those for glucose, lipids, and amino acids via the tricarboxylic acid (TCA) cycle and adjacent metabolic networks. The transportation of monocarboxylates across the cellular membrane is performed primarily by monocarboxylate transporters (MCTs), the membrane localization and stabilization of which are facilitated by the transmembrane protein basigin (BSG). Here, we demonstrate that the MCT/BSG axis sits at a crucial intersection of cellular metabolism. Abolishment of MCT1 in the plasma membrane was achieved by Bsg depletion, which led to gluconeogenesis impairment via preventing the influx of lactate and pyruvate into the cell, consequently suppressing the TCA cycle. This net anaplerosis suppression was compensated in part by the increased utilization of glycogenic amino acids (e.g., alanine and glutamine) into the TCA cycle and by activated ketogenesis through fatty acid β-oxidation. Complementary to these observations, hyperglycemia and hepatic steatosis induced by a high-fat diet were ameliorated in Bsg-deficient mice. Furthermore, Bsg deficiency significantly improved insulin resistance induced by a high-fat diet. Taken together, the plasma membrane–selective modulation of lactate and pyruvate transport through BSG inhibition could potentiate metabolic flexibility to treat metabolic diseases.
登录
查看更多内容
DOI:
10.1016/j.metabol.2018.03.020
发表时间:
2018-08
期刊:
Metabolism: clinical and experimental
影响因子:
--
作者:
Doke T;Ishimoto T;Hayasaki T;Ikeda S;Hasebe M;Hirayama A;Soga T;Kato N;Kosugi T;Tsuboi N;Lanaspa MA;Johnson RJ;Kadomatsu K;Maruyama S
通讯作者:
Maruyama S
影响因子:
4.6
作者:
Ito T;Ishigami M;Matsushita Y;Hirata M;Matsubara K;Ishikawa T;Hibi H;Ueda M;Hirooka Y;Goto H;Yamamoto A
通讯作者:
Yamamoto A
影响因子:
13.5
作者:
Ishimoto, Takuji;Lanaspa, Miguel A.;Rivard, Christopher J.;Roncal-Jimenez, Carlos A.;Orlicky, David J.;Cicerchi, Christina;McMahan, Rachel H.;Abdelmalek, Manal F.;Rosen, Hugo R.;Jackman, Matthew R.;MacLean, Paul S.;Diggle, Christine P.;Asipu, Aruna;Inaba, Shinichiro;Kosugi, Tomoki;Sato, Waichi;Maruyama, Shoichi;Sanchez-Lozada, Laura G.;Sautin, Yuri Y.;Hill, James O.;Bonthron, David T.;Johnson, Richard J.
通讯作者:
Johnson, Richard J.
影响因子:
4.8
作者:
Burgess, Shawn C.;Leone, Teresa C.;Finck, Brian N.
通讯作者:
Finck, Brian N.
影响因子:
29.4
作者:
Kirk E;Reeds DN;Finck BN;Mayurranjan SM;Patterson BW;Klein S
通讯作者:
Klein S